» Articles » PMID: 38425841

Noninvasive Neuromodulation Protects Against Doxorubicin-induced Cardiotoxicity and Inhibits Tumor Growth

Overview
Journal iScience
Publisher Cell Press
Date 2024 Mar 1
PMID 38425841
Authors
Affiliations
Soon will be listed here.
Abstract

Doxorubicin (Dox) poses a considerable threat to patients owing to its cardiotoxicity, thus limiting its clinical utility. Optimal cardioprotective intervention strategies are needed to suppress tumor growth but also minimize cardiac side effects. Here, we showed that tragus vagus nerve stimulation (tVNS) improved the imbalanced autonomic tone, ameliorated impaired cardiac function and fibrosis, attenuated myocyte apoptosis, and mitochondrial dysfunction compared to those in the Dox group. The beneficial effects were attenuated by methyllycaconitine citrate (MLA). The transcript profile revealed that there were 312 differentially expressed genes and the protection of tVNS and retardation of MLA were related to inflammatory response and NADPH oxidase activity. In addition, tVNS synergizing with Dox inhibited tumor growth and lung metastasis and promoted apoptosis of tumor cells in an anti-tumor immunity manner. These results indicated that non-invasive neuromodulation can play a dual role in preventing Dox-induced cardiotoxicity and suppressing tumor growth through inflammation and oxidative stress.

References
1.
Fradley M, Beckie T, Brown S, Cheng R, Dent S, Nohria A . Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. Circulation. 2021; 144(3):e41-e55. PMC: 8992663. DOI: 10.1161/CIR.0000000000000986. View

2.
Silverman D, Martinez V, Dougherty P, Myers J, Calin G, Amit M . Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk. Cancer Res. 2020; 81(6):1431-1440. PMC: 7969424. DOI: 10.1158/0008-5472.CAN-20-2793. View

3.
Yu L, Huang B, Po S, Tan T, Wang M, Zhou L . Low-Level Tragus Stimulation for the Treatment of Ischemia and Reperfusion Injury in Patients With ST-Segment Elevation Myocardial Infarction: A Proof-of-Concept Study. JACC Cardiovasc Interv. 2017; 10(15):1511-1520. DOI: 10.1016/j.jcin.2017.04.036. View

4.
Oh J, Lee B, Lim G, Lim H, Lee C, Park S . Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition. J Mol Cell Cardiol. 2019; 138:244-255. DOI: 10.1016/j.yjmcc.2019.12.007. View

5.
Lai Y, Zhou X, Guo F, Jin X, Meng G, Zhou L . Non-invasive transcutaneous vagal nerve stimulation improves myocardial performance in doxorubicin-induced cardiotoxicity. Cardiovasc Res. 2021; 118(7):1821-1834. DOI: 10.1093/cvr/cvab209. View